SMC Archives -

Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE review

Phil Taylor Bristol-Myers Squibb, Cabometyx, HEOR, immuno-oncology, Ipsen, kidney cancer, market access, Oncology, Opdivo, SMC 0 Comment

Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo

Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE review

https://pharmaphorum.com/news/scotland-backs-cabometyx-combo-for-kidney-cancer-amid-stalled-nice-review/

Market Access/ News/ News

MHRA grants bluebird ‘innovation passport’ for sickle cell therapy

Phil Taylor bluebird bio, HEOR, innovation passport, MHRA, NICE, rare disease, sickle cell disease, SMC 0 Comment

bluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced

MHRA grants bluebird ‘innovation passport’ for sickle cell therapy

https://pharmaphorum.com/news/mhra-grants-bluebird-innovation-passport-for-sickle-cell-therapy/

Market Access/ News/ News

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

Richard Staines cost-effectiveness, market access, multiple sclerosis, neurology, SMC 0 Comment

Scotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

https://pharmaphorum.com/news/bms-ms-pill-gets-funding-in-scotland-after-rejection-in-england-by-nice/

Market Access/ News/ News

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

Phil Taylor Adcetris, Darzalex, Grifols, HEOR, Janssen, lung cancer, Oncology, Rigel Pharmaceuticals, Roche, Rozlytrek, SMC, Takeda 0 Comment

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

https://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/

Market Access/ News/ News

Scotland says no to Daiichi Sankyo’s cholesterol drug Nilemdo

Phil Taylor cholesterol, Daiichi Sankyo, Nilemdo, SMC 0 Comment

The Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland,

Scotland says no to Daiichi Sankyo’s cholesterol drug Nilemdo

https://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/

Market Access/ News/ News

After NICE okay, Scots denied access to Vifor’s Veltassa

Phil Taylor access, hyperkalaemia, NHS, SMC, Veltassa, Vifor Pharma 0 Comment

The Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor

After NICE okay, Scots denied access to Vifor’s Veltassa

https://pharmaphorum.com/news/after-nice-okay-scots-denied-access-to-vifors-veltassa/

Market Access/ Views & Analysis/ Views and analysis

How does HTA for orphan drugs differ across Europe?

George Underwood England, Europe, France, Germany, HTA, NICE, orphan drugs, Rare diseases, Scotland, SMC, UK 0 Comment

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines

How does HTA for orphan drugs differ across Europe?

https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/

Market Access/ News/ News

Novartis’ Kymriah okayed for funding in Scotland for lymphoma

Richard Staines Kymriah, lymphoma, SMC 0 Comment

Novartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness

Novartis’ Kymriah okayed for funding in Scotland for lymphoma

https://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/

Cancer/ News/ News/ News/ Oncology/ Patients

Scotland backs Pfizer’s Ibrance for breast cancer

Phil Taylor breast cancer, Ibrance, Pfizer, SMC 0 Comment

Pfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced

Scotland backs Pfizer’s Ibrance for breast cancer

https://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/

Trending

SMC

Login